Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

P-nitroaniline is a chromogenic molecule that is used as a dyestuff intermediate in industrial applications. In biochemical research, enzyme assays utilize modified aminoacyl or peptidyl p-nitroanilines as substrates. The enzyme catalyzes the release of free p-nitroaniline, which is the basis of the colorimetric determination of the enzyme activity. Applications of the colorimetric properties of p-nitroanilide include the design of biopolymer drug delivery systems and of solid supports for enzyme immobilization. A kinetic analysis of the α-chymotrypsin catalyzed hydrolysis of aminoacyl and peptidyl p-nitroanilide substrates in vesicles has been reported. It has been shown to possess anti-leishmanial activity.

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.